RYBELSUS® is indicated for the
treatment of adults with insufficiently controlled type 2 diabetes
mellitus to improve glycaemic control as an adjunct to diet and exercise:
• As monotherapy
when metformin is considered inappropriate due to intolerance or contraindications.
• In combination
with other medicinal products for the treatment of diabetes.
For study results with respect to combinations,
effects on glycaemic control and cardiovascular events, and the
populations studied, please refer to the full SmPC1
Click here↗ for
RYBELSUS® prescribing information
RA=glucagon-like peptide-1 receptor agonist
1. Novo Nordisk
Limited; GB & NI RYBELSUS® SmPCs.
| February 2023